Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Research

The pattern of alternative splicing in lung adenocarcinoma shows novel events correlated with tumorigenesis and immune microenvironment

Authors: Gongjun Wang, Weiwei Qi, Liwei Shen, Shasha Wang, Ruoxi Xiao, Wenqian Li, Yuqi Zhang, Xiaoqian Bian, Libin Sun, Wensheng Qiu

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Lung adenocarcinoma (LUAD) is the leading cause of cancer deaths worldwide due to the lack of early diagnostic markers and specific drugs. Previous studies have shown the association of LUAD growth with aberrant alternative splicing (AS). Herein, clinical data of 535 tumor tissues and 59 normal tissues were extracted from The Cancer Genome Atlas (TCGA) database. Each sample was analyzed using the ESTIMATE algorithm; a comparison between higher and lower score groups (stromal or immune) was made to determine the overall- and progression-free survival-related differentially expressed AS (DEAS) events. We then performed unsupervised clustering of these DEASs, followed by determining their relationship with survival rate, immune cells, and the tumor microenvironment (TME). Next, two prognostic signatures were developed using bioinformatics tools to explore the prognosis of cases with LUAD. Five OS- and six PFS-associated DEAS events were implemented to establish a prognostic risk score model. When compared to the high-risk group (HRG), the PFS and OS of the low-risk group (LRG) were found to be considerable. Additionally, a better prognosis was found considerably associated with the ESTIMATE score of the patients as well as immune cells infiltration. Our analysis of AS events in LUAD not only helps to clarify the tumorigenesis mechanism of AS but also provides ideas for revealing potential prognostic biomarkers and therapeutic targets.
Appendix
Available only for authorised users
Literature
1.
Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.PubMed
2.
Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMed
3.
Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84.PubMed
4.
Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge D, et al. Non-small cell lung cancer, Version 6, 2015. J Natl Compr Cancer Netw. 2015;13(5):515–24.
5.
6.
Baralle FE, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017;18(7):437–51.PubMedPubMedCentral
7.
Ge Y, Porse BT. The functional consequences of intron retention: alternative splicing coupled to NMD as a regulator of gene expression. BioEssays. 2014;36(3):236–43.PubMed
8.
Bonnal SC, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer—implications for care. Nat Rev Clin Oncol. 2020;17(8):457–74.PubMed
9.
Climente-González H, Porta-Pardo E, Godzik A, Eyras E. The functional impact of alternative splicing in cancer. Cell Rep. 2017;20(9):2215–26.PubMed
10.
de Necochea-Campion R, Shouse GP, Zhou Q, Mirshahidi S, Chen CS. Aberrant splicing and drug resistance in AML. J Hematol Oncol. 2016;9(1):85.PubMedPubMedCentral
11.
Wan L, Yu W, Shen E, Sun W, Liu Y, Kong J, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 2019;68(1):118–29.PubMed
12.
Sheng J, Zhao Q, Zhao J, Zhang W, Sun Y, Qin P, et al. SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance. EBioMedicine. 2018;38:113–26.PubMedPubMedCentral
13.
Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z, et al. Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 2017;393:40–51.PubMed
14.
Zhao D, Zhang C, Jiang M, Wang Y, Liang Y, Wang L, et al. Survival-associated alternative splicing signatures in non-small cell lung cancer. Aging. 2020;12(7):5878–93.PubMedPubMedCentral
15.
Frankiw L, Baltimore D, Li G. Alternative mRNA splicing in cancer immunotherapy. Nat Rev Immunol. 2019;19(11):675–87.PubMed
16.
Li ZX, Zheng ZQ, Wei ZH, Zhang LL, Li F, Lin L, et al. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. Theranostics. 2019;9(25):7648–65.PubMedPubMedCentral
17.
Yao J, Caballero OL, Huang Y, Lin C, Rimoldi D, Behren A, et al. Altered expression and splicing of ESRP1 in malignant melanoma correlates with epithelial-mesenchymal status and tumor-associated immune cytolytic activity. Cancer Immunol Res. 2016;4(6):552–61.PubMed
18.
Ye ZS, Zheng M, Liu QY, Zeng Y, Wei SH, Wang Y, et al. Survival-associated alternative splicing events interact with the immune microenvironment in stomach adenocarcinoma. World J Gastroenterol. 2021;27(21):2871–94.PubMedPubMedCentral
19.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMed
20.
Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–80.PubMed
21.
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–34.PubMed
22.
Varn FS, Wang Y, Mullins DW, Fiering S, Cheng C. Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment. Can Res. 2017;77(6):1271–82.
23.
Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, et al. The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery. Mol Oncol. 2019;13(5):1166–79.PubMedPubMedCentral
24.
Shaul ME, Eyal O, Guglietta S, Aloni P, Zlotnik A, Forkosh E, et al. Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. FASEB J. 2020;34(3):4204–18.PubMed
25.
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.PubMed
26.
Huang X, Liu J, Mo X, Liu H, Wei C, Huang L, et al. Systematic profiling of alternative splicing events and splicing factors in left- and right-sided colon cancer. Aging. 2019;11(19):8270–93.PubMedPubMedCentral
27.
Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics (Oxford, England). 2017;33(18):2938–40.
28.
Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics (Oxford, England). 2010;26(12):1572–3.
29.
Gao J, Kwan PW, Shi D. Sparse kernel learning with LASSO and Bayesian inference algorithm. Neural Netw. 2010;23(2):257–64.PubMed
30.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.PubMedPubMedCentral
31.
Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.
32.
Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2016;35(19):2413–27.PubMed
33.
Dvinge H, Kim E, Abdel-Wahab O, Bradley RK. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016;16(7):413–30.PubMedPubMedCentral
34.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can Res. 2017;77(21):e108–10.
35.
Bisognin A, Pizzini S, Perilli L, Esposito G, Mocellin S, Nitti D, et al. An integrative framework identifies alternative splicing events in colorectal cancer development. Mol Oncol. 2014;8(1):129–41.PubMed
36.
Shen Q, Nam SW. SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma. BMB Rep. 2018;51(2):57–8.PubMedPubMedCentral
37.
Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara D, Ponce Aix S, et al. Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of Atezolizumab versus Docetaxel in patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(8):1156–70.PubMed
38.
Planchard D, Reinmuth N, Orlov S, Fischer J, Sugawara S, Mandziuk S, et al. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann Oncol. 2020;31(5):609–18.PubMed
39.
Venhuizen J, Jacobs F, Span P, Zegers M. P120 and E-cadherin: double-edged swords in tumor metastasis. Semin Cancer Biol. 2020;60:107–20.PubMed
40.
Deep G, Jain A, Ramteke A, Ting H, Vijendra K, Gangar S, et al. SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin. Mol Cancer. 2014;13:37.PubMedPubMedCentral
41.
Yazdani J, Ghavimi M, Jabbari Hagh E, Ahmadpour F. The role of E-cadherin as a prognostic biomarker in head and neck squamous carcinoma: a systematic review and meta-analysis. Mol Diagn Ther. 2018;22(5):523–35.PubMed
42.
Lechuga S, Amin P, Wolen A, Ivanov AI. Adducins inhibit lung cancer cell migration through mechanisms involving regulation of cell-matrix adhesion and cadherin-11 expression. Biochim Biophys Acta (BBA) Mol Cell Res. 2019;1866(3):395–408.
43.
Papoff G, Presutti D, Lalli C, Bolasco G, Santini S, Manelfi C, et al. CASP4 gene silencing in epithelial cancer cells leads to impairment of cell migration, cell-matrix adhesion and tissue invasion. Sci Rep. 2018;8(1):17705.PubMedPubMedCentral
44.
Singh C, Shyanti R, Singh V, Kale R, Mishra J, Singh RJB, et al. Integrin expression and glycosylation patterns regulate cell-matrix adhesion and alter with breast cancer progression. Biochem Biophys Res Commun. 2018;499(2):374–80.PubMed
45.
Mutvei A, Nagiec M, Hamann J, Kim S, Vincent C, Blenis J. Rap1-GTPases control mTORC1 activity by coordinating lysosome organization with amino acid availability. Nat Commun. 2020;11(1):1416.PubMedPubMedCentral
46.
Zhang L, Chen J, Cheng T, Yang H, Li H, Pan C. Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC). J Cancer. 2020;11(17):4965–79.PubMedPubMedCentral
47.
Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. 2016;22(14):3630–42.PubMedPubMedCentral
48.
Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, et al. RNA immune signatures from pan-cancer analysis are prognostic for high-grade serous ovarian cancer and other female cancers. Cancers. 2020;12(3):620.PubMedCentral
49.
Cramer-Morales K, Heer C, Mapuskar K, Domann F. SOD2 targeted gene editing by CRISPR/Cas9 yields Human cells devoid of MnSOD. Free Radic Biol Med. 2015;89:379–86.PubMedPubMedCentral
50.
Zhou C, Lyu LH, Miao HK, Bahr T, Zhang QY, Liang T, et al. Redox regulation by SOD2 modulates colorectal cancer tumorigenesis through AMPK-mediated energy metabolism. Mol Carcinog. 2020;59(5):545–56.PubMed
51.
Ashtekar A, Huk D, Magner A, La Perle KMD, Boucai L, Kirschner LS. Alterations in Sod2-induced oxidative stress affect endocrine cancer progression. J Clin Endocrinol Metab. 2018;103(11):4135–45.PubMedPubMedCentral
52.
He C, Danes JM, Hart PC, Zhu Y, Huang Y, de Abreu AL, et al. SOD2 acetylation on lysine 68 promotes stem cell reprogramming in breast cancer. Proc Natl Acad Sci USA. 2019;116(47):23534–41.PubMedPubMedCentral
53.
54.
Zhu B, Qi L, Liu S, Liu W, Ou Z, Chen M, et al. CLASP2 is involved in the EMT and early progression after transurethral resection of the bladder tumor. BMC Cancer. 2017;17(1):105.PubMedPubMedCentral
55.
Chen L, Xiong W, Guo W, Su S, Qi L, Zhu B, et al. Significance of CLASP2 expression in prognosis for muscle-invasive bladder cancer patients: a propensity score-based analysis. Urol Oncol. 2019;37(10):800–7.PubMed
56.
Lu W, Lu T, Wei X. Downregulation of DNMT3a expression increases miR-182-induced apoptosis of ovarian cancer through caspase-3 and caspase-9-mediated apoptosis and DNA damage response. Oncol Rep. 2016;36(6):3597–604.PubMed
57.
Han X, Liu D, Zhou Y, Wang L, Hou H, Chen H, et al. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer. Cell Biol Int. 2021;45(1):227–37.PubMed
58.
Cao J, Huang Z, Ou S, Wen F, Yang G, Miao Q, et al. circ0093740 promotes tumor growth and metastasis by sponging miR-136/145 and upregulating DNMT3A in Wilms tumor. Front Oncol. 2021;11:647352.PubMedPubMedCentral
59.
Chang H, Li B, Zhang X, Meng X. NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer. Biochem Biophys Res Commun. 2020;522(2):292–9.PubMed
60.
Lewis MA, Sharabash N, Miao ZF, Lyons LN, Piccirillo J, Kallogjeri D, et al. Increased IFRD1 expression in human colon cancers predicts reduced patient survival. Dig Dis Sci. 2017;62(12):3460–7.PubMedPubMedCentral
61.
Nath D, Li X, Mondragon C, Post D, Chen M, White JR, et al. Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. Cell Commun Signal. 2019;17(1):120.PubMedPubMedCentral
62.
Yu X, Liang C, Zhang Y, Zhang W, Chen H. Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells. BMC Cancer. 2019;19(1):878.PubMedPubMedCentral
63.
Liu X, Peng H, Liao W, Luo A, Cai M, He J, et al. MiR-181a/b induce the growth, invasion, and metastasis of neuroblastoma cells through targeting ABI1. Mol Carcinog. 2018;57(9):1237–50.PubMed
64.
Lenning M, Fortunato J, Le T, Clark I, Sherpa A, Yi S, et al. Real-Time Monitoring and Analysis of Zebrafish Electrocardiogram with Anomaly Detection. Sensors (Basel, Switzerland). 2017;18(1):61.
65.
Bobić V, Djurić-Jovičić M, Dragašević N, Popović MB, Kostić VS, Kvaščev G. An expert system for quantification of Bradykinesia based on wearable inertial sensors. Sensors (Basel, Switzerland). 2019;19(11):2644.
66.
Jayasinghe R, Cao S, Gao Q, Wendl M, Vo N, Reynolds S, et al. Systematic analysis of splice-site-creating mutations in cancer. Cell Rep. 2018;23(1):270-81.e3.PubMedPubMedCentral
67.
Metadata
Title
The pattern of alternative splicing in lung adenocarcinoma shows novel events correlated with tumorigenesis and immune microenvironment
Authors
Gongjun Wang
Weiwei Qi
Liwei Shen
Shasha Wang
Ruoxi Xiao
Wenqian Li
Yuqi Zhang
Xiaoqian Bian
Libin Sun
Wensheng Qiu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01776-0

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue

Review

Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis

Research

Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

Research article

Early rehabilitation relieves diaphragm dysfunction induced by prolonged mechanical ventilation: a randomised control study

Study protocol

High intensity interval training versus moderate intensity continuous training for people with interstitial lung disease: protocol for a randomised controlled trial

Research article

Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics

Research article

Downregulation of exosomal let-7d and miR-16 in idiopathic pulmonary fibrosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits